Literature DB >> 17300638

Drug toxicity and cost as barriers to community participation in HAT control in the Democratic Republic of Congo.

J Robays1, P Lefèvre, P Lutumba, S Lubanza, V Kande Betu Ku Mesu, P Van der Stuyft, M Boelaert.   

Abstract

INTRODUCTION: Active case-finding programmes by mobile teams are the cornerstone of West African Human African Trypanosomiasis (HAT) control. Low attendance rates of screening and low uptake of treatment after diagnosis are major problems. The objectives of this survey were to explore community perception of HAT, to assess acceptability of control activities and to identify barriers amenable to intervention.
METHODS: In September 2004, we conducted 33 focus group discussions with beneficiaries of the HAT control programme among various ethnic groups in two ecological settings (savannah and fluvial) of the Democratic Republic of Congo.
RESULTS: The population had a very detailed knowledge and understanding of HAT transmission, utility of screening, symptoms and treatment. Melarsoprol treatment was feared for its side effects. The sudden death of previously asymptomatic people during treatment was attributed to witchcraft, to which one becomes more vulnerable when the diagnosis is disclosed in public. Lack of confidentiality was also a problem because HAT carries a stigma as a mental disease. Lumbar punctures, especially when performed in public, were disliked but less feared. Financial barriers were a major obstacle for many patients.
CONCLUSION: Less toxic drugs, lowering financial barriers and improving confidentiality would have considerable impact on the participation in population screening for HAT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17300638     DOI: 10.1111/j.1365-3156.2006.01768.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  22 in total

1.  Ethical Considerations for Global Health Decision-Making: Justice-Enhanced Cost-Effectiveness Analysis of New Technologies for Trypanosoma brucei gambiense.

Authors:  Maria W Merritt; C Simone Sutherland; Fabrizio Tediosi
Journal:  Public Health Ethics       Date:  2018-07-18       Impact factor: 1.940

2.  A CATT negative result after treatment for human African trypanosomiasis is no indication for cure.

Authors:  Veerle Lejon; Dieudonné Mumba Ngoyi; Marleen Boelaert; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2010-01-26

3.  Quantifying the burden of rhodesiense sleeping sickness in Urambo District, Tanzania.

Authors:  Lucas E Matemba; Eric M Fèvre; Stafford N Kibona; Kim Picozzi; Sarah Cleaveland; Alexandra P Shaw; Susan C Welburn
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

4.  Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis.

Authors:  Jose R Franco; Pere P Simarro; Abdoulaye Diarra; Jose A Ruiz-Postigo; Mireille Samo; Jean G Jannin
Journal:  Res Rep Trop Med       Date:  2012-08-23

5.  Human African trypanosomiasis in the Democratic Republic of the Congo: a looming emergency?

Authors:  Epco Hasker; Pascal Lutumba; François Chappuis; Victor Kande; Julien Potet; Anja De Weggheleire; Charles Kambo; Evelyn Depoortere; Bernard Pécoul; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2012-12-13

6.  Prevalence and under-detection of gambiense human African trypanosomiasis during mass screening sessions in Uganda and Sudan.

Authors:  Francesco Checchi; Andrew P Cox; François Chappuis; Gerardo Priotto; Daniel Chandramohan; Daniel T Haydon
Journal:  Parasit Vectors       Date:  2012-08-07       Impact factor: 3.876

7.  Diagnostic accuracy of PCR in gambiense sleeping sickness diagnosis, staging and post-treatment follow-up: a 2-year longitudinal study.

Authors:  Stijn Deborggraeve; Veerle Lejon; Rosine Ali Ekangu; Dieudonné Mumba Ngoyi; Patient Pati Pyana; Médard Ilunga; Jean Pierre Mulunda; Philippe Büscher
Journal:  PLoS Negl Trop Dis       Date:  2011-02-22

8.  Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo.

Authors:  Alain Mpanya; David Hendrickx; Mimy Vuna; Albert Kanyinda; Crispin Lumbala; Valéry Tshilombo; Patrick Mitashi; Oscar Luboya; Victor Kande; Marleen Boelaert; Pierre Lefèvre; Pascal Lutumba
Journal:  PLoS Negl Trop Dis       Date:  2012-01-17

Review 9.  Persistent digestive disorders in the tropics: causative infectious pathogens and reference diagnostic tests.

Authors:  Sören L Becker; Jürg Vogt; Stefanie Knopp; Marcus Panning; David C Warhurst; Katja Polman; Hanspeter Marti; Lutz von Müller; Cedric P Yansouni; Jan Jacobs; Emmanuel Bottieau; Moussa Sacko; Suman Rijal; Fransiska Meyanti; Michael A Miles; Marleen Boelaert; Pascal Lutumba; Lisette van Lieshout; Eliézer K N'Goran; François Chappuis; Jürg Utzinger
Journal:  BMC Infect Dis       Date:  2013-01-24       Impact factor: 3.090

Review 10.  Human african trypanosomiasis diagnosis in first-line health services of endemic countries, a systematic review.

Authors:  Patrick Mitashi; Epco Hasker; Veerle Lejon; Victor Kande; Jean-Jacques Muyembe; Pascal Lutumba; Marleen Boelaert
Journal:  PLoS Negl Trop Dis       Date:  2012-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.